Literature DB >> 17954691

Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.

Miyuki Morozumi1, Satoshi Iwata, Keiko Hasegawa, Naoko Chiba, Reiko Takayanagi, Keita Matsubara, Eiichi Nakayama, Keisuke Sunakawa, Kimiko Ubukata.   

Abstract

Among 380 Mycoplasma pneumoniae isolates from 3,678 pediatric patients with community-acquired pneumonia, 50 macrolide-resistant strains had an A2063G transition in domain V of the 23S rRNA, whereas 5 had an A2064G transition. These resistant strains increased rapidly from April 2002 to December 2006.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17954691      PMCID： PMC2223908          DOI： 10.1128/AAC.00779-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro.

Authors:  N Okazaki; M Narita; S Yamada; K Izumikawa; M Umetsu; T Kenri; Y Sasaki; Y Arakawa; T Sasaki
Journal:  Microbiol Immunol       Date:  2001       Impact factor: 1.955

2.  Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation.

Authors:  Miyuki Morozumi; Keiko Hasegawa; Reiko Kobayashi; Nagako Inoue; Satoshi Iwata; Haruo Kuroki; Naohisa Kawamura; Eiichi Nakayama; Takeshi Tajima; Kouichi Shimizu; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

3.  Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae.

Authors:  Satowa Suzuki; Tsutomu Yamazaki; Mitsuo Narita; Norio Okazaki; Isao Suzuki; Tomoaki Andoh; Mayumi Matsuoka; Tsuyoshi Kenri; Yoshichika Arakawa; Tsuguo Sasaki
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Simultaneous detection of pathogens in clinical samples from patients with community-acquired pneumonia by real-time PCR with pathogen-specific molecular beacon probes.

Authors:  Miyuki Morozumi; Eiichi Nakayama; Satoshi Iwata; Yasuko Aoki; Keiko Hasegawa; Reiko Kobayashi; Naoko Chiba; Takeshi Tajima; Kimiko Ubukata
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

Review 5.  Mycoplasma pneumoniae infections.

Authors:  M R Hammerschlag
Journal:  Curr Opin Infect Dis       Date:  2001-04       Impact factor: 4.915
  5 in total
  60 in total

1.  Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China.

Authors:  Fei Zhao; Min Lv; Xiaoxia Tao; Hui Huang; Binghua Zhang; Zhen Zhang; Jianzhong Zhang
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.

Authors:  Ken B Waites; D M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

4.  Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.

Authors:  Yang Liu; Xinyu Ye; Hong Zhang; Xiaogang Xu; Wanhua Li; Demei Zhu; Minggui Wang
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

Review 5.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

6.  Multilocus variable-number tandem-repeat analysis-confirmed emergence of a macrolide resistance-associated mutation in Mycoplasma pneumoniae during macrolide therapy for interstitial pneumonia in an immunocompromised child.

Authors:  Sébastien Hantz; Fabien Garnier; Olivia Peuchant; Céline Menetrey; Alain Charron; Marie-Cécile Ploy; Cécile Bébéar; Sabine Pereyre
Journal:  J Clin Microbiol       Date:  2012-07-18       Impact factor: 5.948

Review 7.  The macrolide antibiotic renaissance.

Authors:  George P Dinos
Journal:  Br J Pharmacol       Date:  2017-08-10       Impact factor: 8.739

Review 8.  New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections.

Authors:  Ken B Waites; Mitchell F Balish; T Prescott Atkinson
Journal:  Future Microbiol       Date:  2008-12       Impact factor: 3.165

9.  Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.

Authors:  Yasuhiro Kawai; Naoyuki Miyashita; Mika Kubo; Hiroto Akaike; Atsushi Kato; Yoko Nishizawa; Aki Saito; Eisuke Kondo; Hideto Teranishi; Satoko Ogita; Takaaki Tanaka; Kozo Kawasaki; Takashi Nakano; Kihei Terada; Kazunobu Ouchi
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients.

Authors:  Yasuhiro Kawai; Naoyuki Miyashita; Mika Kubo; Hiroto Akaike; Atsushi Kato; Yoko Nishizawa; Aki Saito; Eisuke Kondo; Hideto Teranishi; Tokio Wakabayashi; Satoko Ogita; Takaaki Tanaka; Kozo Kawasaki; Takashi Nakano; Kihei Terada; Kazunobu Ouchi
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.